Ontology highlight
ABSTRACT:
SUBMITTER: Okada M
PROVIDER: S-EPMC5053629 | biostudies-literature | 2016 May
REPOSITORIES: biostudies-literature
Oncotarget 20160501 19
A phase 2 clinical trial investigating the efficacy and safety of AS602801, a newly developed JNK inhibitor, in the treatment of inflammatory endometriosis is complete. We are now examining whether AS602801 acts against human cancer cells in vitro and in vivo. In vitro, AS602801 exhibited cytotoxicity against both serum-cultured non-stem cancer cells and cancer stem cells derived from human pancreatic cancer, non-small cell lung cancer, ovarian cancer and glioblastoma at concentrations that did ...[more]